Механизм действия водного раствора жизни против ишемического инсульта на основе протеомики

  • role: First author第一作者
  • Affiliation:

    Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China

  • Email:ljt02052921@163.com
  • Introduction:E-mailljt02052921@163.com
LIU Jingtong1,  
  • Affiliation:

    Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China

HU Shaowei1,  
  • Affiliation:

    Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China

CHANG Mengli1,  
  • Affiliation:

    Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China

XU Jing1,  
  • Affiliation:

    Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China

CAI Qingqing1,  
  • Affiliation:

    School of Pharmacy,Zunyi Medical University,Zunyi 563099,China

LI Xinghong2,  
  • Affiliation:

    Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China

TANG Liying1,  
  • role: Corresponding author通信作者
  • Affiliation:

    Hospital of Integrated Chinese and Western Medicine,Tianjin 300100,China

  • Email:hhwang1103@163.com
  • Introduction:E-mailhhwang1103@163.com *
WANG Huanhuan3*,  
  • role: Corresponding author通信作者
  • Affiliation:

    Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China

  • Email:whw9905012@163.com
  • Introduction:E-mailwhw9905012@163.com
WU Hongwei1*

реферат

Целью является оценка фармакологического воздействия водного раствора жизни на сопротивление мозговому ишемическому инсульту, а также изучение механизма защиты нервов от него. Методы: SPF-самцов крыс разделяли на группу плацебо, группу модели, группы низкой, средней и высокой доз внутривенного вливания водного раствора жизни (3, 6 и 12 мл/кг) и группу положительного лекарства (4 мл/кг золотого моста), каждая группа состояла из 12 особей. Модель ишемического инсульта создавали методом брошурования, затем вводили препарат после восстановления кровотока, курс приема длился 3 дня. Оценивали нервную функцию, площадь мозгового инсульта, окраску гематоксилином и эозином (ГЕ), никелированием, терминальной маркировкой (TUNEL) и методом иммуноблотирования (Western blot) для оценки защитного действия внутривенного вливания водного раствора жизни против повреждения мозга у крыс с ишемическим инсультом. Также выявляли преимущества улучшения мозговых повреждений у крыс с помощью протеомных технологий, с акцентом на белок хлорированного канала 1 (CLIC1) как ключевой белок в сети воздействия. Осязаемая механика была подтверждена на основании модели клеточной ишемии-гипоксии/регенерации-реоксиглюкозы (OGD/R) клеток ПК12 и модели ишемического инсульта у крыс, с использованием методов ферментно-иммунное адсорбентного анализа (ELISA) и Western blot, а также флуоресцентного зонда для хлоридных ионов.

ключеви́че слова́

водный раствор жизни, инсульт от восстановления кровотока, окислительное напряжение, воспалительный ответ, белок хлорированного канала 1 (CLIC1)

References

  1. 1.
    GBD 2019 STROKE COLLABORATORS.Global,regional,and national burden of stroke and its risk factors,1990-2019:A systematic analysis for the global burden of disease study 2019[J].Lancet Neurol,2021,20(10):795-820.
  2. 2.
    Report on Stroke Prevention and Treatment in China Writing Group.Brief report on stroke prevention and treatment in China 2021[J].Chin J Cerebrovasc Dis,2023,20(11):783-793.
  3. 3.
    HILKENS N A,CASOLLA B,LEUNG T W,et al.Stroke[J].Lancet,2024,403(10446):2820-2836.
  4. 4.
    LAN X,WANG Q,LIU Y,et al.Isoliquiritigenin alleviates cerebral ischemia-reperfusion injury by reducing oxidative stress and ameliorating mitochondrial dysfunction via activating the Nrf2 pathway[J].Redox Biol,2024,77:103406.
  5. 5.
    ZHANG A J,WANG S,WANG P,et al.Progress in pathological mechanism of ischemic stroke and prevention and treatment of traditional Chinese medicine[J].Chin J Exp Tradit Med Form,2020,26(5):227-240.
  6. 6.
    QIN C,YANG S,CHU Y H,et al.Signaling pathways involved in ischemic stroke:Molecular mechanisms and therapeutic interventions[J].Signal Transduct Target Ther,2022,7(1):215.
  7. 7.
    HUANG G,ZANG J,HE L,et al.Bioactive nanoenzyme reverses oxidative damage and endoplasmic reticulum stress in neurons under ischemic stroke[J].ACS Nano,2022,16(1):431-452.
  8. 8.
    WANG A A,LI L,LI Y,et al.Research progress on Chinese medicinal material-derived active polypeptides against ischemic cardiovascular and cerebrovascular diseases[J].China J Chin Mater Med,2021,46(21):5576-5584.
  9. 9.
    SHI L P,ZHANG Y G,MA Y,et al.Research status on the role of traditional Chinese medicine in the treatment of ischemic stroke[J].Chin J Clin Pharmacol,2023,39(23):3495-3498.
  10. 10.
    ZHENG X,CHENG S,GAO Y,et al.Efficacy and safety of traditional Chinese medicine for acute ischemic stroke by resolving phlegm and unblocking fu-organs:A systematic review and meta-analysis[J].J Ethnopharmacol,2024,323:117660.
  11. 11.
    QI D H,MA H,DING M M,et al.Study on the mechanism of Shengmai injection in the treatment of cerebral ischemia-reperfusion injury based on the theory of simultaneous treatment of heart and brain[J].J Liaoning Univ Tradit Chin Med,2023,25(6):28-37.
  12. 12.
    CAO Z H,PAN J H,LI N,et al.Modern pharmacological effect and mechanism of Shengmai San[J].Chin J Exp Tradit Med Form,2019,25(22):212-218.
  13. 13.
    XIE L Q,HAN G X.Research progress of Chinese and western medicine on acute ischemic stroke[J].Chin J Convalescent Med,2019,28(10):1047-1050.
  14. 14.
    WANG H,TANG L,HU S,et al.Chemical profiling of Shengmai injection,tissue distribution and pharmacokinetic characteristics of ginsenosides after intravenous dosing Shengmai injection in rats with cerebral ischemia[J].J Ethnopharmacol,2024,319(Pt 1):117119.
  15. 15.
    YANG H,LI L,ZHOU K,et al.Shengmai injection attenuates the cerebral ischemia/reperfusion induced autophagy via modulation of the AMPK, mTOR and JNK pathways[J].Pharm Biol,2016,54(10):2288-2297.
  16. 16.
    ZHENG B H,ZHAN S Y,ZHOU H Y,et al.Research progress on material composition,pre-clinical pharmacokinetic,and pharmacodynamic studies of Shengmai injection[J].Chin Tradit Herbal Drugs,2020,51(20):5360-5371.
  17. 17.
    GAI X H,LIU S X,REN T,et al.Advances research on chemical constituents,preparations and adverse reactions of Ginkgo biloba[J].Drug Eval Res,2017,40(6):742-751.
  18. 18.
    LI G P,LI Y L.Observation of therapeutic efficacy of Ginaton injection in acute ischemic stroke[J].Chin J Mod Drug Appl,2015,9(3):156-157.
  19. 19.
    AVERAIMO S,MILTON R H,DUCHEN M R,et al.Chloride intracellular channel 1(CLIC1):Sensor and effector during oxidative stress[J].FEBS Lett,2010,584(10):2076-2084.
  20. 20.
    XU Y,ZHU J,HU X,et al.CLIC1 inhibition attenuates vascular inflammation,oxidative stress,and endothelial injury[J].PLoS One,2016,11(11):e0166790.
  21. 21.
    DENG Q M,HU Y Q,YUAN L,et al.Research progress in rat models with cerebral ischemia/reperfusion prepared by suture-occluded method[J].West J Tradit Chin Med,2024,37(11):97-100.
  22. 22.
    XU J,WANG T,GUO F,et al.Systematical identification of the protective effect of Danhong injection and Buchang Naoxin Tong capsules on transcription factors in cerebral ischemia mice brain[J].Oxid Med Cell Longev,2020,2020:5879852.
  23. 23.
    DOMINGO-FERNÁNDEZ R,COLL R C,KEARNEY J,et al.The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1β transcription and activate the NLRP3 inflammasome[J].J Biol Chem,2017,292(29):12077-12087.
  24. 24.
    DONG Y L,LI J Y,ZHANG Y H,et al.Advances in the study of immunoinflammatory mechanisms and treatment of Chinese medicine in ischemic stroke[J].World Chin Med,2024,19(2):291-297.
  25. 25.
    XU Z,LI Y,PI P,et al.B.glomerulata promotes neuroprotection against ischemic stroke by inhibiting apoptosis through the activation of PI3K/Akt/mTOR pathway[J].Phytomedicine,2024,132:155817.
  26. 26.
    DATTA A,SARMAH D,MOUNICA L,et al.Cell death pathways in ischemic stroke and targeted pharmacotherapy[J].Transl Stroke Res,2020,11(6):1185-1202.
  27. 27.
    ZHONG M,WEI L L,YANG X F,et al.Research progress in intrinsic and extrinsic mechanism of cell apoptosis[J].Pract J Clin Med,2014,11(2):170-174.
  28. 28.
    ZHANG S J,ZHAO H P,LUO Y M.Clinical and basic research of Shengmai injection in the disease of nervous system[J].Life Sci Inst,2018,16(2):28-33.
  29. 29.
    CHAMORRO Á,DIRNAGL U,URRA X,et al.Neuroprotection in acute stroke:Targeting excitotoxicity,oxidative and nitrosative stress,and inflammation[J].Lancet Neurol,2016,15(8):869-881.
  30. 30.
    LI Z,BI R,SUN S,et al.The role of oxidative stress in acute ischemic stroke-related thrombosis[J].Oxid Med Cell Longev,2022,2022:8418820.
  31. 31.
    BRIYAL S,RANJAN A K,GULATI A.Oxidative stress:A target to treat Alzheimer's disease and stroke[J].Neurochem Int,2023,165:105509.
  32. 32.
    ALSBROOK D L,DI NAPOLI M,BHATIA K,et al.Neuroinflammation in acute ischemic and hemorrhagic stroke[J].Curr Neurol Neurosci Rep,2023,23(8):407-431.
  33. 33.
    LIU Q,JIN W N,LIU Y,et al.Brain ischemia suppresses immunity in the periphery and brain via different neurogenic innervations[J].Immunity,2017,46(3):474-487.
  34. 34.
    DUAN W L,WANG X J,MA Y P,et al.Therapeutic strategies targeting the NLRP3-mediated inflammatory response and pyroptosis in cerebral ischemia/reperfusion injury(Review)[J].Mol Med Rep,2024,29(3):46.
  35. 35.
    FU J,WU H.Structural mechanisms of NLRP3 inflammasome assembly and activation[J].Annu Rev Immunol,2023,41:301-316.
  36. 36.
    ALISHAHI M,FARZANEH M,GHAEDRAHMATI F,et al.NLRP3 inflammasome in ischemic stroke:As possible therapeutic target[J].Int J Stroke,2019,14(6):574-591.

Читать полностью

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website